RT Journal Article
T1 Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.
A1 Hofstra, L Marije
A1 Sauvageot, Nicolas
A1 Albert, Jan
A1 Alexiev, Ivailo
A1 Garcia, Federico
A1 Struck, Daniel
A1 Van de Vijver, David A M C
A1 Åsjö, Birgitta
A1 Beshkov, Danail
A1 Coughlan, Suzie
A1 Descamps, Diane
A1 Griskevicius, Algirdas
A1 Hamouda, Osamah
A1 Horban, Andrzej
A1 Van Kasteren, Marjo
A1 Kolupajeva, Tatjana
A1 Kostrikis, Leondios G
A1 Liitsola, Kirsi
A1 Linka, Marek
A1 Mor, Orna
A1 Nielsen, Claus
A1 Otelea, Dan
A1 Paraskevis, Dimitrios
A1 Paredes, Roger
A1 Poljak, Mario
A1 Puchhammer-Stöckl, Elisabeth
A1 Sönnerborg, Anders
A1 Staneková, Danica
A1 Stanojevic, Maja
A1 Van Laethem, Kristel
A1 Zazzi, Maurizio
A1 Zidovec Lepej, Snjezana
A1 Boucher, Charles A B
A1 Schmit, Jean-Claude
A1 Wensing, Annemarie M J
K1 HIV-1
K1 Drug resistance
K1 Transmission
K1 Antiretroviral therapy
K1 Europe
K1 Benzoxazinas
K1 Intervalos de confianza
K1 Resistencia a medicamentos
K1 Europa (Continente)
K1 Infecciones por VIH
K1 Mutación
K1 Prevalencia
K1 Inhibidores de proteasas
K1 Salud pública
K1 Inhibidores de la transcriptasa inversa
K1 Rilpivirina
K1 Encuestas y Cuestionarios
AB BACKGROUNDNumerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline resistance data enable transmitted drug resistance (TDR) to be surveyed for public health purposes. The SPREAD program systematically collects data to gain insight into TDR occurring in Europe since 2001.METHODSDemographic, clinical, and virological data from 4140 antiretroviral-naive human immunodeficiency virus (HIV)-infected individuals from 26 countries who were newly diagnosed between 2008 and 2010 were analyzed. Evidence of TDR was defined using the WHO list for surveillance of drug resistance mutations. Prevalence of TDR was assessed over time by comparing the results to SPREAD data from 2002 to 2007. Baseline susceptibility to antiretroviral drugs was predicted using the Stanford HIVdb program version 7.0.RESULTSThe overall prevalence of TDR did not change significantly over time and was 8.3% (95% confidence interval, 7.2%-9.5%) in 2008-2010. The most frequent indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutations (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%) and protease inhibitor mutations (2.0%). Baseline mutations were most predictive of reduced susceptibility to initial NNRTI-based regimens: 4.5% and 6.5% of patient isolates were predicted to have resistance to regimens containing efavirenz or rilpivirine, respectively, independent of current NRTI backbones.CONCLUSIONSAlthough TDR was highest for NRTIs, the impact of baseline drug resistance patterns on susceptibility was largest for NNRTIs. The prevalence of TDR assessed by epidemiological surveys does not clearly indicate to what degree susceptibility to different drug classes is affected.
PB Oxford University Press
SN 1058-4838
YR 2016
FD 2016-03-01
LK http://hdl.handle.net/10668/2306
UL http://hdl.handle.net/10668/2306
LA en
NO Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, et al. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. Clin. Infect. Dis. 2016; 62(5):655-63
NO Journal Article;
DS RISalud
RD Apr 10, 2025